Frontline Sevabertinib Approved in HER2-Mutant NSCLC: Nursing Priorities

The FDA has granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.) for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. This decision expands the indication for sevabertinib to frontline treatment-naive patients.